Review

lipid nanoparticle-encapsulated mrna vaccine bnt162b1 (BioNTech)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

BioNTech lipid nanoparticle-encapsulated mrna vaccine bnt162b1
Lipid Nanoparticle Encapsulated Mrna Vaccine Bnt162b1, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bnt162b1+vaccine/bnt162b1/pm40333293-226-2-0
Average 90 stars, based on 1 article reviews

lipid nanoparticle-encapsulated mrna vaccine bnt162b1 - by Bioz Stars, 2026-09

90/100 stars

Images

Vaccines:

Article Title: Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial
Article Snippet: .. The study also extends our understanding of immune persistence and the safety of the BNT162b1 vaccine in the context of other vaccines in the BioNTech pipeline. .. This study was funded by BioNTech SE and Shanghai Fosun Pharmaceutical Development.

other:

Article Title: Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies.
Article Snippet: COVID-19 has caused a global pandemic and millions of deaths.. It is imperative to develop effective countermeasures against the causative viral agent, SARS-CoV-2 and its many variants.. Vaccines and therapeutic antibodies are the most effective approaches for preventing and treating COVID-19, respectively.

Article Title: SARS-CoV-2 Vaccination and the Multi-Hit Hypothesis of Oncogenesis
Article Snippet: Phase I/II clinical trials with the BNT162b1 (Pfizer/BioNTech) [ ] and ChAdOx1 (Oxford/AstraZeneca) [ ] vaccines described a dose-dependent decrease in plasma lymphocytes 6-8 days post-vaccination in 45%-46% of participants.

Article Title: Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial
Article Snippet: This study further extends our understanding of immune persistence and the safety of the BNT162b1 vaccine as a candidate vaccine in the BioNTech pipeline.

Immunopeptidomics:

Article Title: mRNA vaccines: Past, present, future
Article Snippet: .. Pfizer/BioNTech first developed the BNT162b1 vaccine which consists of an LNP-formulated, nucleoside-modified mRNA encoding the RBD of the S glycoprotein of SARS-CoV-2, trimerized by addition of a T4 fibritin foldon domain so as to increase its immunogenicity. ..